Literature DB >> 81990

Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan.

D W Hedley, T J McElwain, J L Millar, M Y Gordon.   

Abstract

7 patients with advanced malignant melanoma who were given cyclophosphamide (500 mg intravenously) 7 days before a high dose of melphalan (140 mg/m2) had a more rapid recovery of the peripheral white-cell count than did 4 patients who received melphalan alone. "Priming" by cyclophosphamide might be a practicable means of offsetting the bone-marrow toxicity of some chemotherapy regimens and it may permit higher doses of drugs to be given safely.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 81990     DOI： 10.1016/s0140-6736(78)92529-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  17 in total

1.  The effect of pretreatment with thio-TEPA and cytosine arabinoside on megakaryocytopoiesis in rats given a sublethal dose of thio-TEPA.

Authors:  G Tanum; A Sønstevold; A Engeset
Journal:  Blut       Date:  1987-01

2.  High dose melphalan with autologous bone marrow transplantation in the treatment of metastatic Ewing's sarcoma.

Authors:  S R McCann; M Reynolds; R Meldrum; B Breslin; T Walsh; I J Temperley; P A Daly
Journal:  Ir J Med Sci       Date:  1983-04       Impact factor: 1.568

Review 3.  [Hematopoietic stimulation for enhanced bone marrow regeneration after chemotherapy (author's transl)].

Authors:  L Labedzki; D Noack
Journal:  Klin Wochenschr       Date:  1980-03-03

Review 4.  The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Authors:  Christina L Grek; Danyelle M Townsend; Kenneth D Tew
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

5.  Influence of scheduling on two-drug combinations of alkylating agents in vivo.

Authors:  B A Teicher; S A Holden; S M Jones; J P Eder; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancer.

Authors:  R Osborne; B Evans; C Gallagher; C Wood; M Slevin; J Shepherd; E Wiltshaw
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Pharmacokinetics of high-dose melphalan in children and adults.

Authors:  A Gouyette; O Hartmann; J L Pico
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 8.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine.

Authors:  L Hogarth; M English; L Price; R Wyllie; A D Pearson; A G Hall
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.

Authors:  A Zimber; K Perk; I Livnat
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.